Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches

Proteome Science

Volumn 12, Issue 1, 2014, Pages

  Popescu, Ionela D ^a,b   Codrici, Elena ^a   Albulescu, Lucian ^a,e   Mihai, Simona ^a   Enciu, Ana Maria ^a,c   Albulescu, Radu ^a,d   Tanase, Cristiana P ^a  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b UNIVERSITY OF BUCHAREST   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d NATIONAL INSTITUTE FOR CHEMICAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Romania)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; CXCL4; Glioblastoma; LC MS MS; S100A8; S100A9; SELDI ToF MS

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CHEMOKINE; CXCL4 CHEMOKINE; PROTEOME; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANION EXCHANGE; ARTICLE; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRACTIONATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MOLECULAR WEIGHT; MOLECULE; OXIDATION; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

EID: 84909998152     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/s12953-014-0047-0     Document Type: Article

References (67)

1. Kocevar N, Hudler P, Komel R. The progress of proteomic approaches in searching for cancer biomarkers. N Biotechnol 2013, 30:319-326. 10.1016/j.nbt.2012.11.011, 23165098.
2. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 2007, 110:13-24. 10.1002/cncr.22741, 17520692.
3. Wei P, Zhang W, Yang LS, Zhang HS, Xu XE, Jiang YH, Huang FP, Shi Q. Serum GFAP autoantibody as an ELISA-detectable glioma marker. Tumour Biol 2013, 34:2283-2292. 10.1007/s13277-013-0770-7, 23589055.
4. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010, 60:166-193. 10.3322/caac.20069, 20445000.
5. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 2002, 9:24-36. 10.1097/00125480-200201000-00004, 11756757.
6. Kalinina J, Peng J, Ritchie JC, Van Meir EG. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 2011, 13:926-942. 10.1093/neuonc/nor078, 21852429.
7. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, Naumov GN, Bender E, Almog N, Italiano JE, Folkman J, Klement GL. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008, 111:1201-1207. 10.1182/blood-2007-04-084798, 17914028.
8. Chen S, Zhao H, Deng J, Liao P, Xu Z, Cheng Y. Comparative proteomics of glioma stem cells and differentiated tumor cells identifies S100A9 as a potential therapeutic target. J Cell Biochem 2013, 114:2795-2808. 10.1002/jcb.24626, 23836528.
9. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006, 27:251-259. 10.1016/j.tips.2006.03.003, 16600386.
10. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Buchler MW, Friess H. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007, 34:205-214. 10.1097/01.mpa.0000250128.57026.b2, 17312459.
11. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, Teodoru M, Tanase CP: Cytokine Patterns in Brain Tumour Progression.Mediators Inflamm 2013, ID 979748, doi:10.1155/2013/979748..
12. Jaunalksne I, Donina S, Pirtnieks A, Grusina-Ujumaza J, Spaka I, Babjoniseva A, Krievins D. Dynamics of CXC group chemokine platelet factor 4 (PF4) plasma levels in non-small cell lung cancer (NSCLC). J Transl Med 2012, 10(Suppl 3):9.
13. Pilatova K, Greplova K, Demlova R, Bencsikova B, Klement GL, Zdrazilova-Dubska L. Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology. J Hematol Oncol 2013, 6:42. 10.1186/1756-8722-6-42, 23800319.
14. Somasundaram K, Nijaguna MB, Kumar DM. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 2009, 9:695-707. 10.1586/erm.09.52, 19817554.
15. Tanase CP, Enciu AM, Mihai S, Neagu AI, Calenic B, Cruceru ML. Anti-cancer Therapies in High Grade Gliomas. Curr Proteonomics 2013, 10:246-260. 10.2174/1570164611310030007.
16. Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Canc Manag Res 2014, 6:149-170.
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109. 10.1007/s00401-007-0243-4, 17618441.
18. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007, 48:403-407. 10.1002/pbc.20803, 16609952.
19. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010, 16:1597-1604. 10.1158/1078-0432.CCR-09-2902, 20160062.
20. Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One 2012, 7:e41036. 10.1371/journal.pone.0041036, 22829908.
21. Popescu ID, Albulescu R, Raducan E, Dinischiotu A, Tanase C. Applications of SELDI-TOF technology in cancer biomarkers discovery. Romanian Biotechnol Lett 2010, 15:5654-5667.
22. Azzam S, Broadwater L, Li S, Freeman EJ, McDonough J, Gregory RB. A SELDI mass spectrometry study of experimental autoimmune encephalomyelitis: sample preparation, reproducibility, and differential protein expression patterns. Proteome Sci 2013, 11:19. 10.1186/1477-5956-11-19, 23635033.
23. Forshed J, Pernemalm M, Tan CS, Lindberg M, Kanter L, Pawitan Y, Lewensohn R, Stenke L, Lehtio J. Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia. J Proteome Res 2008, 7:2332-2341. 10.1021/pr070482e, 18452325.
24. Bai J, He A, Zhang W, Huang C, Yang J, Yang Y, Wang J, Zhang Y. Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling. Proteome Sci 2013, 11:39. 10.1186/1477-5956-11-39, 23915341.
25. Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2009, 47:713-723. 10.1515/CCLM.2009.158, 19426140.
26. Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol 2008, 31:133-139. 10.1097/COC.0b013e318145b98b, 18391596.
27. Lin Q, Peng Q, Yao F, Pan XF, Xiong LW, Wang Y, Geng JF, Feng JX, Han BH, Bao GL, Yang Y, Wang X, Jin L, Guo W, Wang JC. A classification method based on principal components of SELDI spectra to diagnose of lung adenocarcinoma. PLoS One 2012, 7:e34457. 10.1371/journal.pone.0034457, 22461913.
28. Wegdam W, Moerland PD, Meijer D, de Jong SM, Hoefsloot HC, Kenter GG, Buist MR, Aerts JM. A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass. Proteome Sci 2012, 10:45. 10.1186/1477-5956-10-45, 22824475.
29. Liu C, Pan C, Liang Y. Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma. Exp Ther Med 2012, 3:1005-1009. 22970007.
30. Gautam P, Nair SC, Gupta MK, Sharma R, Polisetty RV, Uppin MS, Sundaram C, Puligopu AK, Ankathi P, Purohit AK, Chandak GR, Harsha HC, Sirdeshmukh R. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS One 2012, 7:e46153. 10.1371/journal.pone.0046153, 23029420.
31. Li Z, Lu H, Yang J, Zeng X, Zhao L, Li H, Liao Q, Peng S, Zhou M, Wu M, Xiang J, Wang Y, Li G. Analysis of the raw serum peptidomic pattern in glioma patients. Clin Chim Acta 2013, 425:221-226. 10.1016/j.cca.2013.08.002, 23954773.
32. Sandset PM. CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer. Thromb Res 2012, 129(Suppl 1):S97-S100. 10.1016/S0049-3848(12)70026-9, 22682144.
33. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M. TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 2008, 13:217-236. 10.1080/13547500701676019, 18270872.
34. Vandercappellen J, Van Damme J, Struyf S. The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev 2011, 22:1-18. 10.1016/j.cytogfr.2010.10.011, 21111666.
35. Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb Res 2010, 125:292-296. 10.1016/j.thromres.2009.11.023, 20004006.
36. Van Raemdonck K, Gouwy M, Lepers SA, Van Damme J, Struyf S. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase. Angiogenesis 2014, 17:631-640. 10.1007/s10456-014-9417-6, 24469069.
37. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis?. Lancet 1998, 352:1775-1777. 10.1016/S0140-6736(98)05095-8, 9848370.
38. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schutte C, Hauss J, Buchler M, Thiery J. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 2009, 15:3812-3819. 10.1158/1078-0432.CCR-08-2701, 19470732.
39. Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010, 19:2605-2610. 10.1158/1055-9965.EPI-10-0178, 20729288.
40. Zaldivar MM, Pauels K, von Hundelshausen P, Berres ML, Schmitz P, Bornemann J, Kowalska MA, Gassler N, Streetz KL, Weiskirchen R, Trautwein C, Weber C, Wasmuth HE. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010, 51:1345-1353. 10.1002/hep.23435, 20162727.
41. Peterson JE, Zurakowski D, Italiano JE, Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012, 15:265-273. 10.1007/s10456-012-9259-z, 22402885.
42. Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005, 5:2927-2938. 10.1002/pmic.200401165, 15952230.
43. Wiesner T, Bugl S, Mayer F, Hartmann JT, Kopp HG. Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis 2010, 27:141-149. 10.1007/s10585-010-9311-6, 20182908.
44. Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 2012, 11:3. 10.1186/1476-4598-11-3, 22236567.
45. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72:1622-1631. 10.1016/j.bcp.2006.05.017, 16846592.
46. Srikrishna G. S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun 2012, 4:31-40. 10.1159/000330095, 21912088.
47. Parris TZ, Kovacs A, Aziz L, Hajizadeh S, Nemes S, Semaan M, Forssell-Aronsson E, Karlsson P, Helou K. Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma. Int J Cancer 2014, 134:1617-1629. 10.1002/ijc.28497, 24114735.
48. Xu Y, Cao LQ, Jin LY, Chen ZC, Zeng GQ, Tang CE, Li GQ, Duan CJ, Peng F, Xiao ZQ, Li C. Quantitative proteomic study of human lung squamous carcinoma and normal bronchial epithelial acquired by laser capture microdissection. J Biomed Biotechnol 2012, 2012:510418. 22500095.
49. Hu Y, Fan B, Zhang LH, Cheng XJ, Niu ZJ, Ji JF. Clinical significance of S100A8 and S100A9 expression in gastric cancer. Zhonghua Yi Xue Za Zhi 2013, 93:3369-3374. 24418034.
50. Duan L, Wu R, Ye L, Wang H, Yang X, Zhang Y, Chen X, Zuo G, Weng Y, Luo J, Tang M, Shi Q, He T, Zhou L. S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/beta-catenin pathway. PLoS One 2013, 8:e62092. 10.1371/journal.pone.0062092, 23637971.
51. Chen KT, Kim PD, Jones KA, Devarajan K, Patel BB, Hoffman JP, Ehya H, Huang M, Watson JC, Tokar JL, Yeung AT. Potential prognostic biomarkers of pancreatic cancer. Pancreas 2014, 43:22-27. 10.1097/MPA.0b013e3182a6867e, 24326364.
52. McNeill E, Hogg N. S100A9 has a protective role in inflammation-induced skin carcinogenesis. Int J Cancer 2014, 135:798-808. 10.1002/ijc.28725, 24436096.
53. Grebhardt S, Veltkamp C, Strobel P, Mayer D. Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer 2012, 131:2785-2794. 10.1002/ijc.27591, 22505354.
54. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 2009, 18:47-56. 10.3727/096504009789954672, 20066894.
55. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008, 181:4666-4675. 10.4049/jimmunol.181.7.4666, 18802069.
56. Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, Breuhahn K, Gebhardt C, Schirmacher P, Hahn M, Ben-Neriah Y, Pikarsky E, Angel P, Hess J. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 2009, 50:1251-1262. 10.1002/hep.23099, 19670424.
57. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 2006, 312:184-197. 10.1016/j.yexcr.2005.10.013, 16297907.
58. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34:357-364. 10.1016/j.ejso.2007.04.009, 17566693.
59. Qin F, Song Y, Li Z, Zhao L, Zhang Y, Geng L. S100A8/A9 induces apoptosis and inhibits metastasis of CasKi human cervical cancer cells. Pathol Oncol Res 2010, 16:353-360. 10.1007/s12253-009-9225-2, 19957061.
60. Fan B, Zhang LH, Jia YN, Zhong XY, Liu YQ, Cheng XJ, Wang XH, Xing XF, Hu Y, Li YA, Du H, Zhao W, Niu ZJ, Lu AP, Li JY, Ji JF. Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer. BMC Cancer 2012, 12:316. 10.1186/1471-2407-12-316, 22838504.
61. Jin L, Shen Q, Ding S, Jiang W, Jiang L, Zhu X. Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy. Gynecol Oncol 2012, 126:140-146. 10.1016/j.ygyno.2012.04.005, 22487537.
62. Yong HY, Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res 2007, 30:75-81. 10.1007/BF02977781, 17328245.
63. Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, Kerkhoff C. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol 2009, 625:73-83. 10.1016/j.ejphar.2009.08.044, 19835859.
64. Choi JH, Shin NR, Moon HJ, Kwon CH, Kim GH, Song GA, Jeon TY, Kim DH, Park do Y. Identification of S100A8 and S100A9 as negative regulators for lymph node metastasis of gastric adenocarcinoma. Histol Histopathol 2012, 27:1439-1448. 23018243.
65. Cormier K, Harquail J, Ouellette RJ, Tessier PA, Guerrette R, Robichaud GA. Intracellular expression of inflammatory proteins S100A8 and S100A9 leads to epithelial-mesenchymal transition and attenuated aggressivity of breast cancer cells. Anticancer Agents Med Chem 2013, 14:35-45. 10.2174/18715206113136660333.
66. Li C, Li S, Jia C, Yang L, Song Z, Wang Y. Low concentration of S100A8/9 promotes angiogenesis-related activity of vascular endothelial cells: bridges among inflammation, angiogenesis, and tumorigenesis?. Mediators Inflamm 2012, 2012:248574. 22685372.
67. Grebhardt S, Muller-Decker K, Bestvater F, Hershfinkel M, Mayer D. Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo. J Cell Physiol 2013, 229:661-671. 10.1002/jcp.24489.